These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 30581498)
1. Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis. Li M; Zhao Y; Zhao E; Wang K; Lu W; Yuan L Dis Markers; 2018; 2018():3947626. PubMed ID: 30581498 [TBL] [Abstract][Full Text] [Related]
2. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858 [TBL] [Abstract][Full Text] [Related]
3. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
5. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer. Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer. Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228 [TBL] [Abstract][Full Text] [Related]
7. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265 [TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis. Zhang H; Ge J; Hong H; Bi L; Sun Z World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in DNA repair genes and their association with risk of cervical cancer: A systematic review and meta-analysis. Shao X; Yang X; Liu Y; Song Q; Pan X; Chen W; Jiang W; Xu D; Song Y; Chen R J Obstet Gynaecol Res; 2022 Sep; 48(9):2405-2418. PubMed ID: 35732591 [TBL] [Abstract][Full Text] [Related]
10. Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies. Qian T; Zhang B; Qian C; He Y; Li Y Medicine (Baltimore); 2017 May; 96(20):e6832. PubMed ID: 28514298 [TBL] [Abstract][Full Text] [Related]
11. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253 [TBL] [Abstract][Full Text] [Related]
12. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis. Zhou Q; Fu Y; Wen L; Deng Y; Chen J; Liu K Technol Cancer Res Treat; 2021; 20():1533033821990046. PubMed ID: 33517857 [TBL] [Abstract][Full Text] [Related]
13. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. Chu H; Gu D; Xu M; Xu Z; Gong Y; Gong W; Tang Y; Zhou J; Tong N; Zhang Z; Chen J; Wang M Mutagenesis; 2013 Jul; 28(4):441-6. PubMed ID: 23680703 [TBL] [Abstract][Full Text] [Related]
14. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis. Chen B; Zhou Y; Yang P; Wu XT J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556 [TBL] [Abstract][Full Text] [Related]
15. Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis. Zhang E; Cui Z; Xu Z; Duan W; Huang S; Tan X; Yin Z; Sun C; Lu L BMC Cancer; 2013 Dec; 13():594. PubMed ID: 24330540 [TBL] [Abstract][Full Text] [Related]
16. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Zhang X; Jiang LP; Yin Y; Wang YD Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266 [TBL] [Abstract][Full Text] [Related]
17. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243 [TBL] [Abstract][Full Text] [Related]
18. Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population. Xu Q; Zhang Z; Sun W; Hu B Mamm Genome; 2017 Jun; 28(5-6):227-233. PubMed ID: 28474168 [TBL] [Abstract][Full Text] [Related]
19. Effect of Zhang H; Li Y; Guo S; Wang Y; Wang H; Lu D; Wang J; Jin L; Jiang G; Wu J; Han Y; Li J Am J Transl Res; 2020; 12(10):6941-6953. PubMed ID: 33194084 [TBL] [Abstract][Full Text] [Related]
20. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study. Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]